Proteros and Institut Pasteur Korea Establish Discovery Services Collaboration in the Field of Infectious Diseases
News May 25, 2011
Proteros Biostructures GmbH (Proteros) has announced that it has entered into a service agreement with Institut Pasteur Korea (IP-K) under which Proteros will provide structure-based drug discovery services to IP-K.
Under this collaboration Proteros will apply its know-how, experience of structural analysis and its proprietary X-ray crystallography platform to support IP-K’s mission to develop therapeutics for infectious diseases.
Cony D’Cruz, Chief Business Officer of Proteros, stated, “Institut Pasteur Korea is a world class translational research institute, renowned as a centre of excellence in biomedical research and technology development with a clear focus on infectious and neglected disease. We welcome the opportunity for Proteros to contribute to these efforts.”
Dr. Michel Liuzzi, Director, Early Discovery Program at IP-K, added “We are very pleased with the expertise and know-how of Proteros in providing timely X-ray crystallography support to our in-house drug discovery projects and we look forward to continue collaborating with Proteros in the future.”
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE